This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Translational Prostate Cancer
        • Women in Science
          Andrea Miyahira, Ph.D
        • Health Policy
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
    • Trials in Progress
      • DORA - PCCTC
      • IRONMAN - PCCTC
      • PROMISE - PCCTC
      • SPLASH Trial
      • Oral EPI-7386
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SUO 2022
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Conference Highlights

ASCO GU 2020

ASCO GU 2020 Prostate Cancer

  • Randomized phase 2 study of sipuleucel-T (Sip-T) with or without radium-233 (Ra-223) in men with bone metastatic castration-resistant prostate cancer - Poster
  • ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: The PROfound Trial
  • ASCO GU 2020: A Phase II Study of Talazoparib in Men with DNA Damage Repair Mutations and Metastatic Castration-Resistant Prostate Cancer
  • ASCO GU 2020: Assessment of Inherited DNA Repair Defects in African-American and Caucasian Men with Prostate Cancer
  • ASCO GU 2020: Phase Ib Study of Niraparib plus Androgen Receptor-Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer 
View all (92 articles)

ASCO GU 2020 Kidney Cancer

  • ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Surgeon’s Perspective
  • ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Pathologists Perspective
  • ASCO GU 2020: Comparing Nivolumab versus Everolimus with >5 years of Follow-up in Patients with Advanced Renal Cell Carcinoma: A Final Analysis of the CheckMate 025 Trial
  • ASCO GU 2020: The Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
  • ASCO GU 2020: A Phase I/II Study of Sitravatinib Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cancer that Progressed on Prior Anti-Angiogenic Therapy
View all (57 articles)

ASCO GU 2020 Bladder Cancer

  • ASCO GU 2020: Results from BLASST-1 - Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy.
  • ASCO GU 2020: Combining Chemotherapy with Novel Agents, Opportunities, and Challenges.
  • ASCO GU 2020: (NEO-BLADE) Phase II Randomized Placebo-Controlled Neoadjuvant Trial of Nintedanib or Placebo with Gemcitabine and Cisplatin in Locally Advanced Muscle Invasive Bladder Cancer
  • ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma
  • ASCO GU 2020: The Efficacy of Two Cycles of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Patients.
View all (46 articles)

ASCO GU 2020 Penile, Urethral, Testicular, and Adrenal Cancers

  • ASCO GU 2020: Can Advanced Seminoma be Managed with a Risk Stratified Approach?
  • ASCO GU 2020: Evaluation of the Oncologic Benefit of Adjunctive Surgery at Time of Post-Chemotherapy Retroperitoneal Lymph Node Dissection
  • ASCO GU 2020: Intravesical Irrigation to Prevent Early Bladder Recurrence in Patients Undergoing Laparoscopic Radical Nephroureterectomy for Upper Urinary Tract Cancer
  • ASCO GU 2020: Atezolizumab Therapy for Upper Tract Urothelial Carcinoma: Subgroup Analysis of the Single-Arm International SAUL Study in Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma
  • ASCO GU 2020: Prognostic Factors in Advanced Seminoma — Analysis from the IGCCCG Update Consortium.
View all (20 articles)

ASCO GU 2020 Press Releases

  • ASCO GU: Real World Study Finds Adding Immunotherapy Reduces Death by 45% in Advanced Prostate Cancer
  • Bristol-Myers Squibb Shares Long-Term Survival Results for Nivolumab with or without Ipilimumab in Renal Cell Carcinoma
  • Blue Earth Diagnostics Announces Upcoming Presentations from FALCON Study of Axumin® at ASCO GU 2020
  • Bayer to Highlight Data from its Expanding Cancer Portfolio at 2020 ASCO GU Cancers Symposium
  • miR Scientific Presents Breakthrough New Data on the miR Scientific Sentinel™ Tests for the Detection and Classification of Prostate Cancer at ASCO GU 2020
View all (7 articles)
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free